Jamie E. Chaft, MD - Marking New Milestones With Immunotherapy in Locally Advanced and Early Lung Cancer: Latest Data Informing Best Practices for Multimodal Management of Stage I-III NSCLC

59:16
 
Delen
 

Manage episode 303446924 series 9912
Van PeerView, 24 West 40th Street, Suite 950, New York, NY 10018, PVI, and PeerView Institute for Medical Education, ontdekt door Player FM en onze gemeenschap - copyright toebehorend aan de uitgever, niet aan Player FM. Audio wordt direct van hun servers gestreamd. Klik de abonneren-knop aan om updates op Player FM te volgen of plak de feed URL op andere podcast apps.
Go online to PeerView.com/CBB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The immunotherapy revolution in lung cancer continues, as clinical practice and research build on achievements made in advanced NSCLC and aim to extend the benefits of immunotherapies to earlier stages. Immune checkpoint inhibitor (ICI) therapy is routinely used as consolidation following chemoradiation for patients with stage III unresectable NSCLC. Now, ICIs and rational combinations are starting to show promising activity as neoadjuvant and adjuvant therapies for patients with resectable stage I-III NSCLC as well. Optimal approaches are still being determined, and many questions and controversies remain, but it is essential for oncologists, thoracic surgeons, and other multidisciplinary specialists to work together to make these therapies available to patients with earlier stages of lung cancer. This PeerView educational activity, based on a recent web broadcast, provides essential updates on the evolving science supporting the use of ICIs in multimodal treatment of unresectable and resectable stage I-III NSCLC. Multidisciplinary perspectives on how to make the most of immunotherapies and rational combinations in curative-intent settings are shared as well. Upon completion of this accredited CE activity, participants should be better able to: Characterize the rationale for using immunotherapy as a component of multimodal therapy in locally advanced or earlier stages of non–small cell lung cancer (NSCLC), Review key clinical trials and available efficacy/safety data on immunotherapies and immune-based combinations in locally advanced and earlier stages of NSCLC, Determine the best assessment and treatment approaches for diverse populations of patients with stage I-III NSCLC as part of clinical practice or clinical trials based on the latest evidence and recommendations, effective multidisciplinary and interprofessional collaboration and care coordination, and patient needs, values, and preferences.

503 afleveringen